Logo

Celltrion's Herzuma (Trastuzumab Biosimilar- CT-P6) Receives EMA Approval for Breast Cancer- Metastatic Breast Cancer and Metastatic Gastric Cancer

Share this
Celltrion's Herzuma (Trastuzumab Biosimilar- CT-P6) Receives EMA Approval for Breast Cancer- Metastatic Breast Cancer and Metastatic Gastric Cancer

Celltrion's Herzuma (Trastuzumab Biosimilar- CT-P6) Receives EMA Approval for Breast Cancer- Metastatic Breast Cancer and Metastatic Gastric Cancer

Shots:

  • The approval is based on positive opinion by CHMP (EMA) assessing Herzuma and reference trastuzumab in patients with HER2 overexpression/gene amplification tumors in breast cancer- metastatic breast cancer and metastatic gastric cancer
  • The study resulted in a non-inferiority data demonstrating efficacy- safety- immunogenicity- PD and PK in patients
  • Herzuma (trastuzumab biosimilar- CT-P6) is a mAb- that binds to extracellular domain of human epidermal growth factor receptor (HER2) and is currently reviewed by FDA review in the USS

Ref: Celltrion | Image: Celltrion

 

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions